Loading
Life sciences · Journal article
Cancers · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Lung cancer is the leading cause of cancer death worldwide. However, the molecular mechanisms involved in its development and response to therapies remain poorly understood. Previous studies have unraveled the pro- or anti-tumoral roles of circular RNAs (circRNAs) in numerous cancers. These mostly non-coding RNAs consist of a single-strand RNA forming a stable closed loop. CircRNA expression is often dysregulated in cancers, including lung cancer. An increasing number of studies have been published describing the role of circRNAs in lung tumor progression and/or resistance to therapies. Most of these studies have focused on how circRNAs impact cancer cells in a cell-autonomous manner, but less is known about the role of tumoral circRNAs in the crosstalk between cancer cells and cells from the tumor microenvironment (TME). In this review, focusing on non-small cell lung cancer (NSCLC), we provide a comprehensive and up-to-date analysis of the current knowledge in this emerging field. We highlight key molecular mechanisms by which tumor-derived circRNAs reshape the NSCLC tumor immune microenvironment. We also discuss recent findings showing their contributions to most NSCLC hallmarks, including those newly described in 2022, as well as their involvement in NSCLC’s escape from therapies. All these studies clearly open avenues for translational applications of circRNAs in NSCLC, as either potential biomarkers or therapeutic targets, although current limitations clearly need to be overcome to translate circRNAs into the clinic.